B Cells antibody | FMC7
Mouse anti Human B cells antibody, clone FMC7 recognizes a glycoprotein antigen of ~105 kDa expressed by B lymphocytes. The FMC7 antigen is expressed by peripheral B lymphocytes, and has been used widely in the study of B cell malignancy. Mouse anti Human B cells antibody, clone FMC7 has been used extensively to differentiate various types of B cell malignancy. B-CLL is generally considered to be negative for FMC7 expression, but strong staining is seen in many other types of B cell lymphoma, including prolymphocytic leukemia and hairy cell leukemia.
The nature of the FMC7 antigen has remained poorly defined following its first description in 1981. The expression pattern closely corresponds to that seen with CD22, but studies have shown that FMC7 does not recognize the CD22 molecule itself. Mouse anti Human B cells antibody, clone FMC7 recognizes a conformational epitope on the CD20 molecule, most likely a multimeric complex of CD20 (Serke et al. 2001). Identity of CD20 as the antigen recognized by Mouse anti Human B cells antibody, clone FMC7 was further confirmed by strong recognition of recombinant CD20 expressed in hematopoietic and non-haematopoietic cell lines and abolition of binding in CD20 extracellular domain mutations. The recognized epitope has also been shown to be cholesterol dependent (Polyak et al. 2003).
The nature of the FMC7 antigen has remained poorly defined following its first description in 1981. The expression pattern closely corresponds to that seen with CD22, but studies have shown that FMC7 does not recognize the CD22 molecule itself. Mouse anti Human B cells antibody, clone FMC7 recognizes a conformational epitope on the CD20 molecule, most likely a multimeric complex of CD20 (Serke et al. 2001). Identity of CD20 as the antigen recognized by Mouse anti Human B cells antibody, clone FMC7 was further confirmed by strong recognition of recombinant CD20 expressed in hematopoietic and non-haematopoietic cell lines and abolition of binding in CD20 extracellular domain mutations. The recognized epitope has also been shown to be cholesterol dependent (Polyak et al. 2003).
Product Details
- Target Species
- Human
- Product Form
- Purified IgM conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Preparation
- Purified IgM prepared by gel filtration
- Buffer Solution
- TRIS buffered glycine
- Preservative Stabilisers
- 0.1% Sodium Azide (NaN3)
0.2% Bovine Serum Albumin - Immunogen
- HRIK cells - Human B-Lymphoblastoid line.
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 18 months from date of despatch.
More Information
- UniProt
- P11836 Related reagents
- Entrez Gene
- MS4A1 Related reagents
- GO Terms
- GO:0005887 integral to plasma membrane
- GO:0006955 immune response
- GO:0042113 B cell activation
- Regulatory
- For research purposes only
Applications of B Cells antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry | Neat |
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Negative Isotype Controls Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Mouse IgM Negative Control:FITC | MCA692F | 0.1 mg | F |
Useful Reagents Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Human Seroblock | BUF070A | 50 Test | F | ||
| Human Seroblock | BUF070B | 200 Test | F |
Product Specific References
Source Reference
-
Brooks, D.A. et al. (1981) Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. IV. A monoclonal antibody reacting specifically with a subpopulation of human B lymphocytes.
J Immunol. 126 (4): 1373-7.
References for B Cells antibody
-
Catovsky, D. et al. (1981) Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7.
Blood. 58 (2): 406-8. -
Serke, S. et al. (2001) Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: Evidence from phenotyping after Rituxan therapy and transfectant cell analyses.
Cytometry (Comm. Clin. Cytometry) 46:98-104 -
Zola H., et al. (1984) The human B cell lineage studied with monoclonal antibodies.
In Leucocyte Typing Ed.A. Bernard, Springer Verlag. p363-71. -
Zola, H. et al. (1984) The antigen of mature human B cells detected by the monoclonal antibody FMC7: studies on the nature of the antigen and modulation of its expression.
J Immunol. 133 (1): 321-6. -
Bloem, A.C. et al. (1988) Functional properties of human B cell subpopulations defined by monoclonal antibodies HB4 and FMC7.
J Immunol. 140 (3): 768-73. -
Zola, H. et al. (1987) Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules.
Dis Markers. 5 (4): 227-35. -
Ghia, P. et al. (2003) The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression.
Blood. 101 (4): 1262-9. -
Ferro LM & Zola H (1990) Modulation of expression of the antigen identified by FMC7 upon human B-lymphocyte activation: evidence for differences between activation in vivo and in vitro.
Immunology. 69 (3): 373-8. -
Collins R.J., et al. (1992) Malignant lymphoma: reactive with the monoclonal antibody FMC7.
Pathology 15: 350. -
Zucchetto A et al. (2006) A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia.
J Cell Physiol. 207 (2): 354-63. -
Wang, C. et al. (2002) Differentiation of monoclonal B lymphocytosis of undetermined significance (MLUS) and chronic lymphocytic leukemia (CLL) with weak CD5 expression from CD5(-) CLL.
Leuk Res. 26 (12): 1125-9. -
Amato, D. et al. (2007) Cytogenetic aberrations and immunoglobulin VH gene mutations in clinically benign CD5- monoclonal B-cell lymphocytosis.
Am J Clin Pathol. 128 (2): 333-8. -
Polyak, M.J. et al. (2003) A cholesterol-dependent CD20 epitope detected by the FMC7 antibody.
Leukemia. 17 (7): 1384-9. -
Domingo-Domènech, E. et al. (2002) CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients.
Haematologica. 87 (10): 1021-7. -
Gladkikh, A. et al. (2010) Cyclin D1 expression in B-cell lymphomas.
Exp Hematol. 38 (11): 1047-57. -
Unruh, T.L. et al. (2005) Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.
Immunology. 116 (2): 223-32. -
Gladkikh, A.A. et al. (2017) Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.
Cancer Med. 6 (12): 2984-97.
